| Literature DB >> 28691032 |
Hao Feng1,2,3,4, Hongxia Zhang5, Wen He5, Jian Zhou6, Xingquan Zhao1,2,3,4.
Abstract
The purpose of this study was to determine whether jugular venous reflux (JVR) is associated with perihematomal edema (PHE) in individuals with intracerebral hemorrhage (ICH). Patients with spontaneous supratentorial ICH within 72 h of symptom onset were enrolled. Baseline brain computed tomography (CT) scan was performed, with a follow-up CT examination at 12 ± 3 days after onset. Jugular venous color Doppler ultrasound was performed at 12 ± 3 days after onset to examine the JVR status. A total of 65 patients with ICH were enrolled. In logistic regression analysis, absolute PHE volume was significantly associated with JVR (OR, 5.46; 95% CI, 1.04-28.63; p = 0.044) and baseline hematoma volume (OR, 1.14; 95% CI, 1.03-1.26; p = 0.009) within 72 h of onset. It was also correlated with JVR (OR, 15.32; 95% CI, 2.52-92.99; p = 0.003) and baseline hematoma volume (OR, 1.14; 95% CI, 1.04-1.24; p = 0.006) at 12 ± 3 days after onset. In a similar manner, relative PHE volume was significantly associated with JVR (OR, 14.85; 95% CI, 3.28-67.17; p < 0.001) within 72 h of onset and at 12 ± 3 days after onset (OR, 5.87; 95% CI, 1.94-17.77; p = 0.002). JVR is associated with both absolute and relative PHE volumes after ICH.Entities:
Mesh:
Year: 2017 PMID: 28691032 PMCID: PMC5485297 DOI: 10.1155/2017/7514639
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Retrograde flow detected in the Doppler spectrum spontaneously is considered jugular venous reflux (JVR).
Baseline characteristics and risk factor profiles of patients with ICH.
| JVR negative | JVR positive |
| |
|---|---|---|---|
| Number of subjects, | 36 | 29 | NA |
| Age in years, mean (SD) | 52.9 (12.2) | 55.1 (9.3) | 0.422 |
| Male gender, | 27 (75.0) | 24 (82.8) | 0.449 |
| History of smoking, | 14 (38.9) | 13 (44.8) | 0.629 |
| History of ICH, | 0 (0.0) | 4 (13.8) | 0.075 |
| History of IS, | 4 (11.1) | 3 (10.3) | NA |
| History of CAD, | 2 (5.6) | 2 (6.9) | NA |
| History of hypertension, | 29 (80.6) | 26 (89.7) | 0.506 |
| Irregular shape of hematoma, | 5 (13.9) | 9 (36%) | 0.095 |
| Admission GCS, median (IQR) | 15 (13–15) | 14 (12–15) | 0.264 |
| Admission mRS, median (IQR) | 4 (2–4) | 4 (2–5) | 0.308 |
| Admission NIHSS, mean (SD) | 7.8 (5.1) | 8.4 (5.4) | 0.614 |
| LDL (mmol/L), mean (SD) | 3.1 (0.9) | 2.8 (0.5) | 0.203 |
| GLU (mmol/L), mean (SD) | 5.3 (1.4) | 5.0 (1.3) | 0.509 |
| INR, mean (SD) | 1.00 (0.06) | 1.01 (0.04) | 0.214 |
| First SBP (mmHg), mean (SD)† | 171 (29) | 162 (24) | 0.184 |
| First DBP (mmHg), mean (SD)† | 99 (16) | 100 (15) | 0.771 |
| Baseline hematoma volume (ml), mean (SD) | 19.52 (12.49) | 20.29 (10.85) | 0.794 |
| sIVH, | 6 (16.7) | 5 (17.2) | 1.000 |
| Hematoma location in basal ganglia or thalamus, | 31 (86.1) | 26 (90.0) | 0.958 |
| Intraluminal structural abnormality, | 2 (5.6) | 5 (17.2) | 0.268 |
| Malformed valve | 2 (5.6) | 5 (17.2) | — |
| Flap | 0 | 0 | |
| Web | 0 | 0 | |
| Membrane | 0 | 0 | |
| Septum | 0 | 0 | |
| Extraluminal structural abnormality, | 0 | 0 | — |
NA, not applicable; ICH, intracerebral hemorrhage; IS, ischemic stroke; CAD, coronary artery disease; GCS, Glasgow Coma Scale; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; LDL, low density lipoprotein; GLU, blood glucose; INR, international normalized ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; sIVH, secondary intraventricular hemorrhage; IQR, interquartile range; SD, standard deviation; †first blood pressure measured after symptom observation.
PHE volumes in JVR-negative and JVR-positive groups.
| JVR negative | JVR positive |
| |
|---|---|---|---|
| Within 72 hours | |||
| Absolute PHE volume (ml), mean (SD) | 14.69 (12.80) | 23.15 (14.43) | 0.015 |
| Relative PHE volume, mean (SD) | 0.74 (0.41) | 1.28 (0.65) | <0.001 |
| At 12 ± 3 days | |||
| Absolute PHE volume (ml), mean (SD) | 30.67 (23.63) | 55.56 (30.34) | <0.001 |
| Relative PHE volume, mean (SD) | 2.93 (2.23) | 6.83 (4.32) | <0.001 |
PHE, perihematomal edema; SD, standard deviation.
Numbers of subjects classified based on average PHE volume.
| JVR negative | JVR positive |
| |
|---|---|---|---|
| Baseline absolute PHE† | 0.041 | ||
| Large-volume group, | 12 (41.4) | 1 (58.6) | |
| Small-volume group, | 24 (66.7) | 12 (33.3) | |
| Baseline relative PHE‡ | <0.001 | ||
| Large-volume group, | 6 (24.0) | 19 (76.0) | |
| Small-volume group, | 30 (75.0) | 10 (25.0) | |
| 12 ± 3 days' absolute PHE§ | 0.001 | ||
| Large-volume group, | 8 (30.8) | 18 (69.2) | |
| Small-volume group, | 28 (71.8) | 11 (28.2) | |
| 12 ± 3 days' relative PHE// | 0.001 | ||
| Large-volume group, | 7 (29.2) | 17 (70.8) | |
| Small-volume group, | 29 (70.7) | 12 (29.3) |
PHE, perihematomal edema; †patients classified according to average absolute PHE volume (18.47 ml) within 72 h of onset; ‡patients classified according to average relative PHE volume (0.98) within 72 h of onset; §patients classified according to average absolute PHE volume (41.77 ml) at 12 ± 3 days after onset; //patients classified according to average relative PHE volume (4.67) at 12 ± 3 days after onset.
Odd ratios in multivariate logistic regression analysis.
| OR value (95% CI) |
| |
|---|---|---|
| Based on 72 h absolute PHE† | ||
| JVR | 5.46 (1.04–28.63) | 0.044 |
| Baseline hematoma volume | 1.14 (1.03–1.26) | 0.009 |
| Based on 72 h relative PHE‡ | ||
| JVR | 14.85 (3.28–67.17) | <0.001 |
| Based on absolute PHE at 12 ± 3 days§ | ||
| JVR | 15.32 (2.52–92.99) | 0.003 |
| Baseline hematoma volume | 1.14 (1.04–1.24) | 0.006 |
| Based on relative PHE at 12 ± 3 days// | ||
| JVR | 5.87 (1.94–17.77) | 0.002 |
PHE, perihematomal edema; CI, confidence interval; OR, odds ratio; †patients classified according to average absolute PHE volume within 72 h of onset; ‡patients classified according to average relative PHE volume within 72 h of onset; §patients classified according to average absolute PHE volume at 12 ± 3 days after onset; //patients classified according to average relative PHE volume at 12 ± 3 days after onset.